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A 28-year-old female patient, known for a primary anti-
phospholipid syndrome, presented in 1996 multiple doc-
umented thrombosis of the portal, mesenteric, left
internal iliac and left gonadic veins. Since then, oral
contraception (desogestrel) was stopped and oral antico-
agulation (acenocoumarol) initiated. Regular ambula-
tory international normalized ratio (INR) controls always
remained in the expected therapeutic range (2.0–3.0) and
required only few acenocoumarol dose adjustments.
Six years later, in April 2002, an ambulatory control
revealed an INR value over 8.0 (checked twice). There
was no history or clinical signs of hemorrhage. The only
relevant anamnestic ﬁnding was right shoulder pain for
which rofecoxib 50 mg/day had been taken orally for the
prior 2 weeks. The withdrawal of rofecoxib and the
administration of 4 mg vitamin K along with a tempo-
rary suspension of acenocoumarol brought the INR
back into the therapeutic range. Acenocoumarol was
then restarted and INR remained in the therapeutic
range using previous doses. Genotyping for CYP2C9
indicated a wild type (*1/*1).
Rofecoxib, a highly selective inhibitor of cycloxygen-
ase-2, is extensively metabolized in the liver by reduction
to dihydrorofecoxib and is not expected to have any
clinically signiﬁcant kinetic drug interaction with con-
comitant oral anticoagulants.However, an 8% increase in
themean INR is reportedwhen rofecoxib is given together
with warfarin [1]. Acenocoumarol and warfarin are
administrated as racemic mixtures, whose enantiomers
undergo stereoselective hepatic metabolism by diﬀerent
cytochromes P450 [2]. Absolute oral bioavailability of
R(+)-warfarin increases signiﬁcantly by inhibition of
CYP2C19 in contrast to its dynamically active S())war-
farin, which is mainly metabolized by CYP2C9. Aceno-
coumarol (4-nitrowarfarin), widely used in some
European countries, is chemically closely related to
warfarin and also has stereoselective metabolic pathways
[3]. In contrast to warfarin, the R(+)-enantiomer of
acenocoumarol is in clinical conditions more relevant.
R(+)-acenocoumarol undergoes relatively slow bio-
transformation by CYP2C9, CYP2C19 and CYP1A2,
whereas S())-acenocoumarol, albeit pharmacodynami-
cally active, is promptly and extensively metabolized by
CYP2C9. Polymorphism for CYP2C9 with poor metab-
olizer activity for S()) warfarin and both acenocoumarol
enantiomers has been shown to result in overanticoagu-
lation [4, 5]. Experimental evidences suggest that rofec-
oxib inhibits CYP1A2 and CYP2C19, which are
implicated in the metabolism of the clinically most rele-
vant isomer R(+)-acenocoumarol [1]. Rofecoxib is
therefore susceptible to increase signiﬁcantly the exposure
of R(+)-acenocoumarol by decreasing the clearance,
which clinically may lead to overanticoagulation.
Keeping in mind the above experimental evidence
and considering the chronological relationship between
rofecoxib exposure in this patient, the emergence of a
high INR and the positive outcome after rofecoxib
withdrawal, the imputability of a drug to drug interac-
tion between rofecoxib and acenocoumarol remains
probable.
Practitioners should therefore be particularly cau-
tious when prescribing a high dosage of rofecoxib
simultaneously with the oral anticoagulant acenocou-
marol and closely monitor the INR when initiating or
stopping rofecoxib therapy.
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